Axonics, Inc. Share Price

Equities

AXNX

US05465P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 17/07/2024 BST 5-day change 1st Jan Change
68 USD +0.04% Intraday chart for Axonics, Inc. +0.41% +9.27%
Sales 2024 * 447M 34.4B Sales 2025 * 537M 41.34B Capitalization 3.47B 267B
Net income 2024 * 4M 308M Net income 2025 * 31M 2.39B EV / Sales 2024 * 7.02 x
Net cash position 2024 * 329M 25.32B Net cash position 2025 * 370M 28.49B EV / Sales 2025 * 5.77 x
P/E ratio 2024 *
673 x
P/E ratio 2025 *
109 x
Employees 797
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.04%
1 week+0.41%
Current month+1.15%
1 month+1.07%
3 months+1.19%
6 months-0.53%
Current year+9.27%
More quotes
1 week
67.74
Extreme 67.74
68.19
1 month
67.01
Extreme 67.01
68.19
Current year
55.09
Extreme 55.09
69.68
1 year
48.30
Extreme 48.3
69.68
3 years
38.41
Extreme 38.41
79.92
5 years
15.25
Extreme 15.25
79.92
10 years
11.95
Extreme 11.95
79.92
More quotes
Managers TitleAgeSince
Founder 51 31/12/12
Founder 65 30/09/13
Director of Finance/CFO 39 31/12/13
Members of the board TitleAgeSince
Chairman 53 26/02/19
Director/Board Member 72 07/04/19
Founder 65 30/09/13
More insiders
Date Price Change Volume
17/07/24 68 +0.04% 230,503
16/07/24 67.97 +0.18% 338,737
15/07/24 67.85 +0.07% 192,963
12/07/24 67.8 -0.19% 352,486
11/07/24 67.93 +0.31% 568,899

Delayed Quote Nasdaq, July 17, 2024 at 09:00 pm

More quotes
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat bladder and bowel dysfunction. It has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. It also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
68 USD
Average target price
71.89 USD
Spread / Average Target
+5.72%
Consensus